Our current study provides proof of principle for investigating lactate and alanine metabolism, bioenergetics levels (β-NTP/Pi), and pH using MRS in BRAF/MEK inhibitor-treated patients with metastatic melanoma and possibly other solid tumors. Here, BRAF is linked to metastatic melanoma.